Tempus AI (TEM) may be building one of healthcare's fastest-growing artificial intelligence (AI) platforms, but the stock hasn’t given investors much to celebrate lately. Shares are down roughly 15% over the past year and about 4% year-to-date (YTD), even as the company continues to report strong revenue growth and expand its footprint in AI-powered precision medicine. TEM stock even has an approximately 4% weightage in Cathie Wood’s ARK Invest ETFs (ARKG) (ARKK). With the stock pulling back while the fundamentals continue improving, investors are left with a critical choice.
Does this pullback represent a buying opportunity or a warning sign?